Genprex (GNPX) Cut to “Sell” at Zacks Investment Research

Genprex (NASDAQ:GNPX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday, reports.

According to Zacks, “Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company’s initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small cell lung cancer. Genprex Inc. is based in United States. “

Other analysts also recently issued reports about the company. Maxim Group downgraded Genprex from a “buy” rating to a “hold” rating in a report on Monday, April 1st. ValuEngine downgraded Genprex from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.

Shares of NASDAQ:GNPX traded down $0.05 during trading on Thursday, hitting $1.75. 4,954 shares of the company were exchanged, compared to its average volume of 43,665. The company has a market capitalization of $27.42 million and a PE ratio of -1.94. Genprex has a 1-year low of $0.95 and a 1-year high of $19.45.

Genprex (NASDAQ:GNPX) last posted its quarterly earnings data on Monday, April 1st. The company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.09). Sell-side analysts expect that Genprex will post -0.64 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Genprex stock. Intl Fcstone Inc. acquired a new stake in Genprex Inc (NASDAQ:GNPX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,150 shares of the company’s stock, valued at approximately $39,000. Intl Fcstone Inc. owned 0.23% of Genprex as of its most recent SEC filing. 7.01% of the stock is owned by institutional investors and hedge funds.

Genprex Company Profile

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Recommended Story: How does new data get added to a blockchain?

Get a free copy of the Zacks research report on Genprex (GNPX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with's FREE daily email newsletter.